Senti Biosciences, Inc.
SNTIHealthcare|Biotechnology|US
$0.16
-0.00 (-2.74%)
Cash / Share
$0.21
Analyst Consensus
Buy4 analysts
Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0
Consensus Target
$6.00
Implied Upside
+3650.0%
Low Target
$6.00
High Target
$6.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
—
0 targets
Last Year
$6.00
1 target · +3650% vs price
All Time
$6.00
1 target · +3650% vs price
Rating Trend
Dec 25
4 buy · 0 hold · 0 sell
Jan 26
4 buy · 0 hold · 0 sell
Feb 26
4 buy · 0 hold · 0 sell
Mar 26
4 buy · 0 hold · 0 sell
Apr 26
4 buy · 0 hold · 0 sell
May 26
4 buy · 0 hold · 0 sell
Jun 26
4 buy · 0 hold · 0 sell
Jul 26
4 buy · 0 hold · 0 sell
Aug 26
3 buy · 0 hold · 0 sell
Sep 26
2 buy · 0 hold · 0 sell
Oct 26
2 buy · 0 hold · 0 sell
Nov 26
2 buy · 0 hold · 0 sell
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 21, 2025 | Leerink Partners | Jeffrey La Rosa | $6.00(+230%) | $1.82 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | May 15, 2026 |
| Chardan Capital | maintain | Buy | Mar 30, 2026 |
| Chardan Capital | maintain | Buy | Dec 9, 2025 |
| Chardan Capital | maintain | Buy | Aug 8, 2025 |
| Chardan Capital | maintain | Buy | Jun 12, 2025 |
| Chardan Capital | maintain | Buy | May 2, 2025 |
| Chardan Capital | maintain | Buy | Dec 4, 2024 |
| Chardan Capital | maintain | Buy | Dec 2, 2024 |
| Chardan Capital | maintain | Buy | Aug 15, 2023 |
| Chardan Capital | maintain | Buy | May 11, 2023 |
| Morgan Stanley | maintain | Equal Weight | Mar 24, 2023 |
| Chardan Capital | maintain | Buy | Mar 23, 2023 |
| Chardan Capital | maintain | Buy | Jan 30, 2023 |
| Morgan Stanley | maintain | Equal Weight | Jan 27, 2023 |
| JP Morgan | maintain | Neutral | Dec 16, 2022 |
| Morgan Stanley | maintain | Equal Weight | Oct 7, 2022 |
| B of A Securities | maintain | Buy | Sep 29, 2022 |
| Chardan Capital | maintain | Buy | Sep 23, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.21| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.41 | $-0.27 | $17.0K | $17.0K |
| May 14, 2026 | $-0.14 | $-0.27 | $8.0K | $16.0K |
| Mar 27, 2026 | $-0.53 | $-0.43 | $22.0K | $1.0M |
| Nov 13, 2025 | $-0.69 | $-0.59 | — | $250.0K |
| Aug 7, 2025 | $-0.56 | $-0.90 | — | $500.0K |
| May 6, 2025 | $-1.41 | $-0.58 | — | $1.3M |
| Mar 20, 2025 | $-0.67 | $-3.13 | $5.9M | $2.8M |
| Nov 14, 2024 | $-6.31 | — | — | — |
News
Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 25.7% of Senti Biosciences
Oct 5, 2026defenseworld.net